Johnson & Johnson Submits NDA for Paliperidone
Posted on: Tuesday, 30 October 2007, 15:00 CDT
Johnson & Johnson has submitted a new drug application to the FDA for paliperidone palmitate, an investigational, once-monthly injection for the treatment of schizophrenia and prevention of recurring symptoms.
Paliperidone palmitate is a long-acting injectable ester of the active ingredient in Invega which utilizes Elan's NanoCrystal Technology. If the new drug application (NDA) is approved, paliperidone palmitate will be marketed in the US by Janssen, a subsidiary of Johnson & Johnson dedicated solely to mental health, J&J said.
Schizophrenia is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions, and social withdrawal), as well as by disorganized thinking.
Source: Datamonitor
Related Articles
- Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection
- Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
- Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
- FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia
- Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
- Investigational Drug Paliperidone ER Significantly Delayed Symptom Recurrence In Clinical Study of Patients With Schizophrenia
- Country of Birth As a Risk Factor for Asthma Among Mexican Americans
- Guidelines for the Diagnosis and Treatment of Celiac Disease in Children
 |
 |
User Comments (0)
RSS Feeds